Fig. 2.

As compared with FVIII treatment alone, FXIII cotreatment increases fibrin crosslinking. (A) Representative western blots for fibrin (ogen) after tissue factor-initiated clotting in recalcified hemophilic plasma treated as in Fig. 1. (B) Quantification of γ–γ dimer normalized to Bβ + β-chain. (C) Maximum rate of γ–γ formation (mean ± standard error of the mean [SEM], n = 7, arbitrary units [AU] min⁻¹). (D) Quantification of high molecular weight (HMW) species normalized to Bβ + β-chain. (E) Maximum rate of HMW species formation (mean ± SEM, n = 7, AU min⁻¹). For (B) and (D), two-way ANOVA with the Holm–Sidak multiple comparisons test was used to compare time and treatment. *P < 0.05 versus buffer-treated, FXIII-treated and FVIII-treated samples. For (C) and (E), treatments were compared by the use of repeated measures ANOVA with the Holm–Sidak multiple comparisons test.